Navigation Links
Mass. General-based research center will investigate why immune system fails to control hepatitis C
Date:7/22/2009

A research consortium based at Massachusetts General Hospital (MGH) has been awarded $15 million from the National Institute of Allergy and Infectious Diseases to investigate how the hepatitis C virus (HCV) resists suppression and clearance by the immune system. The five-year grant will support a Cooperative Center for Translational Research in Human Immunology, which also will focus on how some individuals successfully recover from HCV while the infection becomes chronic in most of those infected, with a special emphasis on immunological events in the liver as the site of HCV replication.

"Hepatitis C is a major global health problem for which existing therapies are inadequate," says Raymond Chung, MD, director of Hepatology in the MGH Gastrointestinal Unit and co-director of the research center. "Improving our understanding of how and why the virus consistently evades immune system control should lead us to better ways of treating hepatitis C and possibly other chronic viral infections." Chung will lead a project to better define the role of the liver cells called hepatocytes in the innate and adaptive immune response to HCV infection.

Center co-director Paul Klenerman, PhD, of Oxford University will examine properties of the T cells that migrate to the liver in response to HCV infection. Additional principal investigators and project goals are:

  • Georg Lauer, MD, PhD, MGH Gastrointestinal Unit, and John Wherry, PhD, Wistar Institute investigate the functional capacity of CD4 and CD8 T cells within the liver in chronic HCV infection;
  • Todd Allen, PhD, Ragon Institute of MGH, MIT and Harvard, and Matthew Henn, PhD, Broad Institute of MIT and Harvard examine how selection pressure applied by T cells affects HCV evolution;
  • Gordon Freeman, PhD, Dana-Farber Cancer Institute develop a panel of reagents designed to modulate signaling in key immune cells;
  • Joseph Misdraji, MD, MGH Pathology create a library of liver cells and tissue from HCV-infected and uninfected patients to use in study experiments;
  • Nicholas Haining, MB, ChB, Dana-Farber develop high-throughput technology platforms to examine and modulate signals inhibiting the immune response.

Almost 170 million people worldwide are infected with HCV, 50 to 80 percent of whom will develop chronic hepatitis, which can lead to cirrhosis, liver cancer or liver failure. Identifying the factors that allow HCV to survive in spite of the immune response against the virus may also improve understanding of immune system failure in other chronic infections, including HIV, Epstein-Barr virus, and tuberculosis.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform
2. Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies
3. Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study
4. AIDS Action Asks Mass. Public Health Council to Forge a State AIDS Plan to Help Stop HIV/AIDS Here
5. Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed
6. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
7. Cryo-Cell Announces Celle(SM) Research and Development Collaboration for Chronic Wound Healing Management
8. Zucker Hillside Researchers to Receive Large Federal Grant to Test for the Early Treatment of Schizophrenia
9. Major NIMH research project to test approaches to altering the course of schizophrenia
10. Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says
11. Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... Hospital M&A activity slowed in the second quarter of ... acquisitions rose to 23 in the second quarter, up 15% from the 20 publicly ... announced deals in the year-ago second quarter. Only four of the transactions disclosed a ...
(Date:7/21/2017)... ... ... The House of Yahweh in Abilene, Texas, has written a new post this week that ... to be more open about positive changes. Yisrayl says the use of force is not ... positive way to solve all; yes, all issues, and he is ready to share this ...
(Date:7/21/2017)... ... ... “Kids aren't born knowing how to regulate their emotions any more than ... St. Louis-based positive education company Generation Mindful. To help with that daunting task, she ... , The kit uses colorful, engaging and educational illustrations and games to teach children ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of ... FCPX timeline. This effect isolates horizontal and vertical lines of pixels and sorts their ... rotating or flipping animation and can be changed using a drop-down menu. Create amazing ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
(Date:7/11/2017)... July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing ... patients who suffer from painful intercourse and other painful pelvic pain conditions ... due to menopause. ... VuVatech LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a ...
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
Breaking Medicine Technology: